Phaseline

Companies › Anova Innovation

Anova Innovation: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ANO31905
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 1Pancreatic CancerAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07444541ANO31905Phase 1Pancreatic CancerOncologyAug 2027

From the company's SEC filings

Complete response letters from FDA

Targets

CLDN18 (1)

Companies with the same targets

Astellas AstraZeneca RemeGen Shanghai Institute Of Biological Products Beijing Biotech Sichuan Kelun-Biotech Biopharmaceutical Biokin (Shanghai) Biopharmaceutical Transcenta Therapeutics (Hangzhou) Shanghai Hengrui Pharmaceutical Innovent Biologics (Suzhou)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.